The Prognostic Significance of Measurable (“Minimal”) Residual Disease in Acute Myeloid Leukemia

被引：0
|
作者：
Francesco Buccisano
Christopher S. Hourigan
Roland B. Walter
机构：
[1] University Tor Vergata,Department of Biomedicine and Prevention, Hematology
[2] National Institutes of Health,Myeloid Malignancies Section, Hematology Branch, National Heart, Lung, and Blood Institute
[3] Fred Hutchinson Cancer Research Center,Clinical Research Division
[4] University of Washington,Department of Medicine, Division of Hematology
[5] University of Washington,Department of Epidemiology
来源：
Current Hematologic Malignancy Reports | 2017年 / 12卷
关键词：
Acute myeloid leukemia; Flow cytometry; Minimal residual disease; Next-generation sequencing; Polymerase chain reaction; Prognostication;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：547 / 556
页数：9
相关论文
共 50 条
  • [21] PROGNOSTIC SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE ASSESSED BY MULTIPARAMETRIC FLOW-CYTOMETRY IN CHILDHOOD ACUTE MYELOID LEUKEMIA
    Rizzati, F.
    Buldini, B.
    Rondelli, R.
    Masetti, R.
    Zangrando, A.
    Disaro, S.
    Scarparo, P.
    Bortoloso, E.
    Pession, A.
    Locatelli, F.
    Basso, G.
    HAEMATOLOGICA, 2014, 99 : 528 - 528
  • [22] Identification of Individualized Minimal Residual Disease in Acute Myeloid Leukemia By Flow Cytometry and Its Application of Prognostic Significance
    Sui, Jing-Ni
    Chen, Qiu-Sheng
    Zhang, Yun-Xiang
    Sheng, Yan
    Wu, Jing
    Li, Jun-Min
    Hu, Jiong
    Weng, Xiang-Qin
    Chen, Bing
    BLOOD, 2018, 132
  • [23] Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia
    Mushtaq, Muhammad Umair
    Harrington, Alexandra M.
    Chaudhary, Sibgha Gull
    Michaelis, Laura C.
    Carlson, Karen-Sue B.
    Abedin, Sameem
    Runass, Lyndsey
    Callander, Natalie S.
    Fallon, Michael J.
    Juckett, Mark
    Hall, Aric C.
    Hematti, Peiman
    Mattison, Ryan J.
    Atallan, Ehab L.
    Murthy, Guru Subramanian Guru
    LEUKEMIA & LYMPHOMA, 2021, 62 (01) : 158 - 166
  • [24] Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia
    Roug, Anne Stidsholt
    Ommen, Hans Beier
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (04)
  • [25] Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia
    Anne Stidsholt Roug
    Hans Beier Ommen
    Current Treatment Options in Oncology, 2019, 20
  • [26] Perspective on measurable residual disease testing in acute myeloid leukemia
    Walter, Roland B.
    LEUKEMIA, 2024, 38 (01) : 10 - 13
  • [27] Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia
    Azenkot, Tali
    Jonas, Brian A.
    CANCERS, 2022, 14 (15)
  • [28] Improved detection of measurable residual disease in acute myeloid leukemia
    Zhang, Xuan
    Grimes, H. Leighton
    SCIENCE ADVANCES, 2023, 9 (38)
  • [29] Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling
    Ganzel, Chezi
    Sun, Zhuoxin
    Baslan, Timour
    Zhang, Yanming
    Gonen, Mithat
    Abdel-Wahab, Omar, I
    Racevskis, Janis
    Garrett-Bakelman, Francine
    Lowe, Scott W.
    Fernandez, Hugo F.
    Ketterling, Rhett
    Luger, Selina M.
    Litzow, Mark
    Lazarus, Hillard M.
    Rowe, Jacob M.
    Tallman, Martin S.
    Levine, Ross L.
    Paietta, Elisabeth
    LEUKEMIA RESEARCH, 2022, 123
  • [30] Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors
    Ozdemir, Zehra Narli
    Sahin, Ugur
    Dalva, Klara
    Baltaci, Mehmet Akif
    Uslu, Atilla
    Ozturk, Cemaleddin
    Seval, Guldane Cengiz
    Toprak, Selami Kocak
    Yuksel, Meltem Kurt
    Topcuoglu, Pervin
    Arslan, Onder
    Ozcan, Muhit
    Beksac, Meral
    Ilhan, Osman
    Gurman, Gunhan
    Bozdag, Sinem Civriz
    TURKISH JOURNAL OF HEMATOLOGY, 2021, 38 (02) : 111 - 118
12345